guidance document reaction reporting -...
TRANSCRIPT
![Page 1: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/1.jpg)
![Page 2: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/2.jpg)
Guidance Document For
Spontaneous Adverse Drug
Reaction Reporting
Version: 1.0
Published by
Indian Pharmacopoeia Commission
National Coordination Centre - Pharmacovigilance Programme of India
Ministry of Health & Family Welfare
Governemnt of India
![Page 3: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/3.jpg)
Application for reproduction should be made to
Ghaziabad-201002, India
Tel: (91-120)-2783401
Fax: (91 -120)-2783311
![Page 4: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/4.jpg)
![Page 5: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/5.jpg)
![Page 6: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/6.jpg)
![Page 7: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/7.jpg)
![Page 8: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/8.jpg)
Acknowledgement
![Page 9: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/9.jpg)
![Page 10: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/10.jpg)
Core Expert Committee
Chairman
Ghaziabad
Members
Noida
Member Secretary
, Ghaziabad
![Page 11: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/11.jpg)
![Page 12: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/12.jpg)
Table of ContentS.No. Page
xiii
Introduction 1
Chapter 1. Pharmacovigilance Programme of India 2
2
2
2
3
3
3
3
4
4
Chapter 2. Responsibilities of PvPI Stakeholders 7
7
7
7
8
8
9
9
9
Chapter 3. Reporting of Adverse Drug Reactions 10
10
10
17
18
![Page 13: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/13.jpg)
18
18
18
Chapter 4. Haemovigilance 19
Introduction 19
20
Chapter 5. Guidance for Reporting Adverse Event following
Immunization
21
Introduction 21
22
22
23
24
Chapter 6. Causality Assessment of Adverse Event 31
31
Why causality assessment 31
31
32
Chapter 7. Signal Detection and Evaluation 33
Chapter 8. PvPI and WHO-UMC Collaboration
37
Chapter 9. Risk Management, Communication and Publications 38
38
38
39
ANNEXURES 40
40
48
![Page 14: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/14.jpg)
xiiiPharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
LIST OF ABBREVIATIONS
NIB
![Page 15: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/15.jpg)
![Page 16: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/16.jpg)
1Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Introduction
Scope of Guidance Document
professionals)
![Page 17: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/17.jpg)
2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Chapter 1: Pharmacovigilance Programme of India
1.1 Background
th
1.2 Overview
1.3 Mission
![Page 18: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/18.jpg)
3Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
1.4 Vision
1.5 Scope and Objectives
To promote rational use of medicine
1.5.1 Short term goals
south, east and west of India
1.5.2 Long term goals
![Page 19: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/19.jpg)
4 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
1.6 National Coordination Centre
1.6.1 Organogram of NCC
Finance & Account Officer Principal Scientific Officer
Technical Associate(s)
Secretary- -
Scientific Director,
IPC
Scientific Assistant(s)
Advisor National Scientific Coordinator
NCC
Director, National
Institute of
Biologicals, HvPI
cum
![Page 20: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/20.jpg)
5Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
1.6.2 Committees under NCC
Steering Committee
Working Group
Quality Review Panel
Signal Review Panel
Core Training Panel
![Page 21: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/21.jpg)
6 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
1.7 Communication under PvPI
PvPI - Communication
![Page 22: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/22.jpg)
7Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Chapter 2: Responsibilities of PvPI Stakeholders
2.1 Responsibilities of Stakeholders
2.1.1 Personnel at AMC
(clinicians, dentists, pharmacists, nurses and other healthcare professionals) of the
2.1.2 Personnel at NCC
![Page 23: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/23.jpg)
8 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
2.1.4 Personnel at CDSCO HQ
![Page 24: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/24.jpg)
9Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
2.1.5 Personnel at National Health Programs
2.2 Training to Stakeholders
2.2.1 Roles and Responsibilities of Regional Resource Centres
![Page 25: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/25.jpg)
10 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Chapter 3: Reporting of Adverse Drug Reactions
3.1 Spontaneous Reporting
A spontaneous report is an unsolicited communication by healthcare professionals or consumers,
3.2 Suspected Adverse Drug Reaction Reporting Form
A. Patient Information
1.
![Page 26: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/26.jpg)
11Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
2.
3.
4.
B. Suspected Adverse Reaction
5.
6.
7.
C. Suspected Medications
8. The details of suspected medication(s) such as
9.
‘Yes’
‘No’
‘Unknown’
‘Not Applicable’ or ‘NA’
‘Reduced dose’- If dose at which the reaction occurred is reduced
Not
10.
Yes’
‘No’
‘Unknown’
‘Not Applicable’ or ‘NA’
reaction
‘Re-introduced dose’
![Page 27: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/27.jpg)
12 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
11.
12.
13.
14.
reason for seriousness as:
‘Death’
Note:
‘Life-threatening’
‘Hospitalisation/prolonged’
increased the hospital stay of the patient
‘Disability’
ability to conduct normal life functions
‘Congenital anomaly’
‘Required intervention to prevent permanent impairment/damage’- if
‘Other’ -
15.
‘Fatal’- if the patient dies
‘Continuing’
‘Recovering’
![Page 28: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/28.jpg)
13Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
‘Recovered’
‘Unknown’
D. Reporter
16.
17. The reporter (if trained) must perform the causality assessment
18.
Mandatory Fields Essentially Required items
reaction, reaction term(s), date
of onset of reaction, suspected reaction, suspected medication(s), dose,
date of therapy started, indication of use,
Note:
![Page 29: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/29.jpg)
14 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
SP
EC
IME
N C
OP
Y
![Page 30: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/30.jpg)
15Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
3.3 Who can Report?
All healthcare professionals (clinicians, dentists, pharmacists, nurses etc) and non-healthcare
professionals including consumers can report suspected adverse drug reaction. Pharmaceutical
3.4 Why to Report?
As a healthcare professional, it is a moral responsibility to report adverse reactions associated
with use of medicines and safeguard the health of public. The safety of more than 1.2 billion
the patient and government. India has a vast genetic and ethnic variability with different disease
prevalence. Use of multi-modal practices, poor patient compliance are the other factors requires
ADR reporting.
3.5 What to Report?
In order to foster the culture of reporting, PvPI encourages reporting of all types of suspected
ADRs- irrespective of whether they are known or unknown, serious or non-serious, frequent
or rare and regardless of a established causal relationship. Although pharmacovigilance is
primarily concerned with pharmaceutical medicines and vaccines, adverse reactions associated
with drugs used in traditional medicine (e.g. herbal remedies), medical devices, contrast media
with the drug use in pregnancy, lactation, paediatric and geriatric. In addition, the reporting
defects (spurious and adulterated drugs) is recommended. Reporting of ADRs encountered with
abuse, off-label use, misuse or occupational exposure is not currently included in PvPI, however
3.6 How and Whom to Report?
website of IPC (www.ipc.gov.in) as well as CDSCO (www.cdsco.nic.in) to report any ADR.
submit it to the coordinator or technical associate of the respective AMC. A reporter who is not
reporter can also mail the form at [email protected].
![Page 31: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/31.jpg)
16 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
1800-180-3024
3.7 Establishment of an AMC
3.8 Data Flow
3.9 Assessment of Individual Case Safety Reports
for:
![Page 32: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/32.jpg)
17Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
1. Quality of documentation:
2. Coding:
3. Relevance:
New drug -
Unknown reaction-
Serious reaction-
4. reports:
5. Causality assessment:
3.10 Utilization of the Data
1. Signal generation and strengthening:
2. Risk Management:
by coordinated and economical application of resources to minimize, monitor, and control
3. Drug regulation:
4. Education:
![Page 33: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/33.jpg)
18 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
3.11 Reporting Requirements in Special Population
3.11.1 Pregnancy and Breastfeeding
Pregnancy
Breastfeeding
3.11.2 Paediatric and Geriatrics
3.11.3 Reporting in the Event of a Public Health Emergency
![Page 34: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/34.jpg)
19Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Chapter 4: Haemovigilance Programme of India (HvPI)
4.1 Introduction
1.
2.
th
![Page 35: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/35.jpg)
20 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
4.2 Transfusion Reaction Reporting Form (TRRF)
SP
EC
IME
N C
OP
Y
![Page 36: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/36.jpg)
21Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Chapter 5: Guidance for Reporting Adverse Event
following Immunization
5.1 Introduction
![Page 37: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/37.jpg)
22 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
5.2 Adverse Events following Immunization - Reporting Form
c 55
5.2.1
SP
EC
IME
N C
OP
Y
![Page 38: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/38.jpg)
23Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
c 66
5.2.2
SP
EC
IME
N C
OP
Y
![Page 39: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/39.jpg)
24 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reportingc 77
5.2.3
SP
EC
IME
N C
OP
Y
![Page 40: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/40.jpg)
25Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
c 88
SP
EC
IME
N C
OP
Y
![Page 41: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/41.jpg)
26 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
c 99
SP
EC
IME
N C
OP
Y
![Page 42: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/42.jpg)
27Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
c 00
SP
EC
IME
N C
OP
Y
![Page 43: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/43.jpg)
28 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
c 11
SP
EC
IME
N C
OP
Y
![Page 44: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/44.jpg)
29Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
c 22
SP
EC
IME
N C
OP
Y
![Page 45: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/45.jpg)
30 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
c 33
SP
EC
IME
N C
OP
Y
![Page 46: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/46.jpg)
31Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Chapter 6: Causality Assessment of Adverse Event
6.2 Why Causality Assessment?
6.3 Advantages and Limitations of Standardised Case Causality Assessment
What causality assessment can do What causality assessment cannot do
assessors
![Page 47: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/47.jpg)
32 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
6.4 WHO-UMC Causality Assessment Scale
Causality term Assessment criteria
Certain
Probable/ Likely
Possible
unclear
Unlikely
impossible)
C o n d i t i o n a l /
Additional data under examination
U n a s s e s s a b l e /
contradictory
![Page 48: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/48.jpg)
33Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Chapter 7: Signal Detection and Evaluation
Si
or approach, the basic
![Page 49: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/49.jpg)
34 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
![Page 50: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/50.jpg)
35Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Chapter 8: PvPI and WHO-UMC Collaboration
8.1 VigiFlow
8.2 VigiBase
8.3 VigiMine
![Page 51: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/51.jpg)
36 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
8.4 VigiMed
8.5 VigiSearch
8.6 VigiLyze
![Page 52: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/52.jpg)
37Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
8.7 VigiFlow-Demo Chart
![Page 53: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/53.jpg)
38 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Chapter 9: Risk Management, Communication and
Publications
9.1 Risk Management
coordinated and economical application of resources to minimize, monitor, and control the
1.
2.
3.
9.2 Communication
![Page 54: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/54.jpg)
39Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Press Communication
Website
Newsletter
9.3 Publications
![Page 55: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/55.jpg)
40 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Annexure 1: Contact details of AMC under PvPI
S. No State Centre Name Coordinator name Email Contact Number
1.
Andhra Pradesh
2.
3.
4.
Tirupati,
5.
Budhawarpet,
6. 08942278112,
7.
Assam
Guwahati-781032
8.
Silchar-788014
9.
Barbheta,
10.
Bihar11.
12.
13. Chhattisgarh
14. Goa
Tiswadi-403202
15.
Gujarat
16.
![Page 56: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/56.jpg)
41Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
17
Gujarat
18.
19.
20.
21.
22.
23.
Anandpura,
24.
Haryana
09990942044
25.
Sciences,
26.
27.
Ambala-133207
28.
Himachal
Pradesh
29.
Shimla-171001
30.
J&K
31.
Sciences, Soura,
32.
Bye pass,
33.
34.
Jharkhand
![Page 57: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/57.jpg)
42 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
35.
Karnataka
09448292424
36.
37.
38.
39.
40. 09449208478
41.
42.
43.
44.
45.
82, Nallurahalli,
46.
47.
48.
Sattur,
49.
Kerala
09447180783
50.
51.
![Page 58: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/58.jpg)
43Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
52.
Kerala
53.
54.
55.
56.
Madhya Pradesh
57.
58.
59.
60.
61.
Maharashtra
62.
63.
64.
65.
400022
66.
442012
09921418999
67.
68.
69.
400012
70. 09890384074
71. 09820377409
![Page 59: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/59.jpg)
44 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
72.
Maharashtra
73.
74.
75. Manipur
Lamphelpat,
76.
Meghalaya
77.
Odisha78.
79. 09437271809
80. 09437304089
81.
Punjab
Ludhiana-141008
82.
Ludhiana-141001
83.
84. 0183-2870200,
2870204
85.
86.
Amritsar-143001
87.
Rajasthan
88. 09414324182
89.
90.
Bhopalpura,
91.
92. 0291-2740329,
2980149
![Page 60: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/60.jpg)
45Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
93. Sikkim
94.
Tamil Nadu
95.
96.
97.
98. 09840279010
99.
100.
Alwarpuram,
101.
102. 09443113740
103.
Telangana
104.
105.
106.
107.
108.
109.
Tripura110.
111.
Uttar Pradesh
112.
113.
![Page 61: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/61.jpg)
46 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
114.
Uttar Pradesh
115. 07897038922
116.
Allahabad- 211002
117.
Ghaziabad-201001
118.
119.
Area, Ghasipur,
09897878728
120.
121.
122. 09794979717
123.
Bhosale
124.
125.
Uttarakhand
09412017320
126.
127.
128.
129.
130.
West Bengal131.
132.
![Page 62: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/62.jpg)
47Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
133.
West Bengal
09831130980
134.
Burdwan-71310
135 09433349332
136.
137.
com
138.
139.
Berhampore-742101
09007924708
S. No Union Territory Centre Name Coordinator name Email Contact Number
140. Chandigarh
141.
Delhi
142.
143.
144.
145.
146.
147.
148.
149.
Puducherry
08940702938
150. 09842778988
![Page 63: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/63.jpg)
48 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Annexure 2: Terminologies used in Pharmacovigilance
Absolute risk
Adverse event
Adverse (drug) reaction (ADR)
A response which is noxious and unintended, and which occurs at doses normally used in humans
Association
Attributable risk
![Page 64: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/64.jpg)
49Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Biological products
Causal relationship
Causality assessment
CIOMS
Clinical trial
![Page 65: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/65.jpg)
50 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Cohort Event Monitoring
Common Epidemiology
Co-morbidities
Compliance
Congenital Anomalies
Control group
Critical terms
Data-mining
![Page 66: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/66.jpg)
51Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Dechallenge
Disproportionality analysis
Drug Abuse
Effectiveness/risk
Epidemiology
Essential medicines
![Page 67: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/67.jpg)
52 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
EVMPD
EUDRAGENE
Excipients
Formulary
Generic (multisource product)
Harm
![Page 68: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/68.jpg)
53Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
ICH
ICD
Incidence
The extent or rate of occurrence, especially the number of new cases of a disease in a population
Individual Case Safety Report
MedDRA
Medical error
Over the counter (OTC)
Off-label-use
When the medicinal product is intentionally used for a medical purpose not in accordance with
Overdose
![Page 69: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/69.jpg)
54 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Pharmacoepidemiology
Pharmacology
Pharmacovigilance
Phocomelia
The term comes from
Placebo
Polypharmacy
Post-authorization safety study (PASS)
Post-marketing
Predisposing factors
![Page 70: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/70.jpg)
55Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Pre-marketing
Prescription event monitoring (PEM)
Prescription only medicine (POM)
Prophylaxis
PSUR
QPPV
Rare
Rational drug use
Rechallenge
Reference risk
![Page 71: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/71.jpg)
56 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
to a reference population, as closely comparable to the exposed population as possible, apart
Regulatory authority
Relative risk
Risk
SAEC
Serious Adverse Event or Reaction
results in death
![Page 72: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/72.jpg)
57Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Side effect
Signal
Spontaneous reporting
SUSAR (Suspected Unexpected Serious Adverse Drug Reaction)
Summary of Product Characteristics
![Page 73: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/73.jpg)
58 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Teratogen
Traditional Medicines
Uncommon
Unexpected adverse reaction
VigiBase
WHO-ART
WHO Drug Dictionary (WHO-DD)
![Page 74: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/74.jpg)
59Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Annexure 3: Organisations, societies, regulators and
useful websites
1. The Central Drugs Standard Control Organisation Headquarters
2. WHO Collaborating Centre for International Drug Monitoring:
The Uppsala Monitoring Centre
![Page 75: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/75.jpg)
60 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
4. National Institute of Biologicals
operations are carried out in the state of the art facility of the institute and in close coordination
5. International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use
![Page 76: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/76.jpg)
61Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Annexure 4: Literature Resources for
Pharmacovigilance
Books
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
![Page 77: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/77.jpg)
62 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
Journals/ Publications & Newsletters
( )
![Page 78: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/78.jpg)
63Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
( )
![Page 79: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/79.jpg)
64 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse Drug Reaction Reporting
The Lancet
(News Bulletin)
![Page 80: Guidance Document Reaction Reporting - WHOapps.who.int/medicinedocs/documents/s23300en/s23300en.pdf · 2 Pharmacovigilance Programme of India : Guidance Document for Spontaneous Adverse](https://reader033.vdocuments.us/reader033/viewer/2022042105/5e831f176f993444a0155f4a/html5/thumbnails/80.jpg)